Cargando…

The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis

BACKGROUND: The neuropeptide somatostatin is one of the major regulatory peptides in the central nervous system and the digestive tract. Our recent work has delineated an association between fibrosis and low levels of endogenous somatostatin plasma levels in Schistosoma mansoni infected subjects. Ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, Shyama, Vrolix, Gunther, Depoortere, Inge, Peeters, Theo, Van Marck, Eric
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1166555/
https://www.ncbi.nlm.nih.gov/pubmed/15949036
http://dx.doi.org/10.1186/1471-2334-5-45
_version_ 1782124425033809920
author Chatterjee, Shyama
Vrolix, Gunther
Depoortere, Inge
Peeters, Theo
Van Marck, Eric
author_facet Chatterjee, Shyama
Vrolix, Gunther
Depoortere, Inge
Peeters, Theo
Van Marck, Eric
author_sort Chatterjee, Shyama
collection PubMed
description BACKGROUND: The neuropeptide somatostatin is one of the major regulatory peptides in the central nervous system and the digestive tract. Our recent work has delineated an association between fibrosis and low levels of endogenous somatostatin plasma levels in Schistosoma mansoni infected subjects. Based on these results this paper explores the therapeutic potential of somatostatin in a mouse model of hepatic fibrosis associated with S. mansoni infections. METHODS: Groups of outbred Swiss mice were infected with 100 S. mansoni cercariae, infection maintained till weeks 10 or 14, and then somatostatin therapy delivered in two regimens – Either a one or a two-day treatment. All animals were sacrificed one week after therapy and controlled for liver, spleen and total body weight. Circulating somatostatin levels in mice plasma were measured at the time of sacrifice by means of a radio-immuno assay. GraphPad Prism(® )was used for statistical calculations. RESULTS: Somatostatin administration showed little toxicity, probably due to its short half-life. Total liver and spleen weights of S. mansoni infected animals increased over time, with no changes observed due to somatostatin therapy. Total body weights were decreased after infection but were not affected by somatostatin therapy. Snap frozen liver sections were stained with haematoxylin-eosin or Masson's trichrome to study parasite count, hepatocyte status, granuloma size and cellularity. After somatostatin treatment mean egg counts per liver section (43.76 ± 3.56) were significantly reduced as compared to the egg counts in untreated mice after 10 weeks of infection (56.01 ± 3.34) (P = 0.03). Similar significant reduction in parasite egg counts were also observed after somatostatin treatment at 14 weeks of infection (56.62 ± 3.02) as compared to untreated animals (69.82 ± 2.77)(P = 0.006). Fibrosis was assessed from the spectrophotometric determination of tissue hydroxyproline. Infection with S. mansoni caused increased hydroxyproline levels (9.37 ± 0.63 μmol at wk10; 9.65 ± 0.96 μmol at wk14) as compared to uninfected animals (1.06 ± 0.10 μmol). This significant increase in collagen content (P = 0.01; 0.007 respectively) marks the fibrosis observed at these time points. Treatment with somatostatin resulted in a significant decrease in hydroxyproline levels both at wk10 (4.76 ± 0.58 μmol) and at wk14 (5.8 ± 1.13 μmol) (P = 0.01; 0.03 respectively). Endogenous somatostatin levels were increased at wk10 (297 ± 37.24 pg/ml) and wk14 (206 ± 13.30 pg/ml) of infection as compared to uninfected mice (119 ± 11.99 pg/ml) (P = 0.01; 0.008 respectively). Circulating somatostatin levels in infected animals were not significantly affected by somatostatin treatment. Hepatocyte status remained unaltered and granulomas were not remarkably changed in size or cellularity. CONCLUSION: Our experiments reveal an antifibrotic effect of somatostatin in schistosomiasis. We have previously shown that the somatostatin receptors SSTR2 and SSTR3 are present on the parasite egg and worms. We therefore hypothesize that somatostatin reduces either the number of parasite eggs or the secretion of fibrosis inducing-mediators. Our data suggest somatostatin may have therapeutic potential in S. mansoni mediated liver pathology.
format Text
id pubmed-1166555
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-11665552005-06-30 The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis Chatterjee, Shyama Vrolix, Gunther Depoortere, Inge Peeters, Theo Van Marck, Eric BMC Infect Dis Research Article BACKGROUND: The neuropeptide somatostatin is one of the major regulatory peptides in the central nervous system and the digestive tract. Our recent work has delineated an association between fibrosis and low levels of endogenous somatostatin plasma levels in Schistosoma mansoni infected subjects. Based on these results this paper explores the therapeutic potential of somatostatin in a mouse model of hepatic fibrosis associated with S. mansoni infections. METHODS: Groups of outbred Swiss mice were infected with 100 S. mansoni cercariae, infection maintained till weeks 10 or 14, and then somatostatin therapy delivered in two regimens – Either a one or a two-day treatment. All animals were sacrificed one week after therapy and controlled for liver, spleen and total body weight. Circulating somatostatin levels in mice plasma were measured at the time of sacrifice by means of a radio-immuno assay. GraphPad Prism(® )was used for statistical calculations. RESULTS: Somatostatin administration showed little toxicity, probably due to its short half-life. Total liver and spleen weights of S. mansoni infected animals increased over time, with no changes observed due to somatostatin therapy. Total body weights were decreased after infection but were not affected by somatostatin therapy. Snap frozen liver sections were stained with haematoxylin-eosin or Masson's trichrome to study parasite count, hepatocyte status, granuloma size and cellularity. After somatostatin treatment mean egg counts per liver section (43.76 ± 3.56) were significantly reduced as compared to the egg counts in untreated mice after 10 weeks of infection (56.01 ± 3.34) (P = 0.03). Similar significant reduction in parasite egg counts were also observed after somatostatin treatment at 14 weeks of infection (56.62 ± 3.02) as compared to untreated animals (69.82 ± 2.77)(P = 0.006). Fibrosis was assessed from the spectrophotometric determination of tissue hydroxyproline. Infection with S. mansoni caused increased hydroxyproline levels (9.37 ± 0.63 μmol at wk10; 9.65 ± 0.96 μmol at wk14) as compared to uninfected animals (1.06 ± 0.10 μmol). This significant increase in collagen content (P = 0.01; 0.007 respectively) marks the fibrosis observed at these time points. Treatment with somatostatin resulted in a significant decrease in hydroxyproline levels both at wk10 (4.76 ± 0.58 μmol) and at wk14 (5.8 ± 1.13 μmol) (P = 0.01; 0.03 respectively). Endogenous somatostatin levels were increased at wk10 (297 ± 37.24 pg/ml) and wk14 (206 ± 13.30 pg/ml) of infection as compared to uninfected mice (119 ± 11.99 pg/ml) (P = 0.01; 0.008 respectively). Circulating somatostatin levels in infected animals were not significantly affected by somatostatin treatment. Hepatocyte status remained unaltered and granulomas were not remarkably changed in size or cellularity. CONCLUSION: Our experiments reveal an antifibrotic effect of somatostatin in schistosomiasis. We have previously shown that the somatostatin receptors SSTR2 and SSTR3 are present on the parasite egg and worms. We therefore hypothesize that somatostatin reduces either the number of parasite eggs or the secretion of fibrosis inducing-mediators. Our data suggest somatostatin may have therapeutic potential in S. mansoni mediated liver pathology. BioMed Central 2005-06-10 /pmc/articles/PMC1166555/ /pubmed/15949036 http://dx.doi.org/10.1186/1471-2334-5-45 Text en Copyright © 2005 Chatterjee et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Chatterjee, Shyama
Vrolix, Gunther
Depoortere, Inge
Peeters, Theo
Van Marck, Eric
The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis
title The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis
title_full The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis
title_fullStr The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis
title_full_unstemmed The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis
title_short The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis
title_sort therapeutic effect of the neuropeptide hormone somatostatin on schistosoma mansoni caused liver fibrosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1166555/
https://www.ncbi.nlm.nih.gov/pubmed/15949036
http://dx.doi.org/10.1186/1471-2334-5-45
work_keys_str_mv AT chatterjeeshyama thetherapeuticeffectoftheneuropeptidehormonesomatostatinonschistosomamansonicausedliverfibrosis
AT vrolixgunther thetherapeuticeffectoftheneuropeptidehormonesomatostatinonschistosomamansonicausedliverfibrosis
AT depoortereinge thetherapeuticeffectoftheneuropeptidehormonesomatostatinonschistosomamansonicausedliverfibrosis
AT peeterstheo thetherapeuticeffectoftheneuropeptidehormonesomatostatinonschistosomamansonicausedliverfibrosis
AT vanmarckeric thetherapeuticeffectoftheneuropeptidehormonesomatostatinonschistosomamansonicausedliverfibrosis
AT chatterjeeshyama therapeuticeffectoftheneuropeptidehormonesomatostatinonschistosomamansonicausedliverfibrosis
AT vrolixgunther therapeuticeffectoftheneuropeptidehormonesomatostatinonschistosomamansonicausedliverfibrosis
AT depoortereinge therapeuticeffectoftheneuropeptidehormonesomatostatinonschistosomamansonicausedliverfibrosis
AT peeterstheo therapeuticeffectoftheneuropeptidehormonesomatostatinonschistosomamansonicausedliverfibrosis
AT vanmarckeric therapeuticeffectoftheneuropeptidehormonesomatostatinonschistosomamansonicausedliverfibrosis